WAM
AVDL

Wolverine Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Wolverine Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-940
Closed -$9.88K – 1569
2024
Q4 		$9.88K Sell
940
-972
-51% -$11.8K ﹤0.01% 1361
2024
Q3 		$25.1K Hold
1,912
– – ﹤0.01% 1249
2024
Q2 		$26.9K Buy
+1,912
New +$31.2K ﹤0.01% 1234
2024
Q1 		– Sell
-5,912
Closed -$83.5K – 1672
2023
Q4 		$83.5K Hold
5,912
– – ﹤0.01% 1144
2023
Q3 		$60.9K Hold
5,912
– – ﹤0.01% 1207
2023
Q2 		$97.4K Buy
+5,912
New +$76.9K ﹤0.01% 1075
2021
Q4 		– Sell
-7,791
Closed -$76K – 2045
2021
Q3 		$76K Hold
7,791
– – ﹤0.01% 1350
2021
Q2 		$52K Hold
7,791
– – ﹤0.01% 1658
2021
Q1 		$70K Hold
7,791
– – ﹤0.01% 1543
2020
Q4 		$52K Sell
7,791
-2,700
-26% -$16.9K ﹤0.01% 1322
2020
Q3 		$52K Buy
+10,491
New +$76.3K ﹤0.01% 1258
2014
Q3 		– Sell
-6,002
Closed -$90K – 2450
2014
Q2 		$90K Buy
+6,002
New +$72.4K ﹤0.01% 1186

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wolverine Asset Management's AVDL Position: Q1 2025 in Review

Wolverine Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 940 shares — an estimated $9.88K sold.

Wolverine Asset Management first reported a position in AVDL in Q2 2014 and held it in 12 quarters. The position peaked at $97.4K in Q2 2023. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Wolverine Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 940 Avadel Pharmaceuticals shares in Q1 2025, an estimated $9.88K.
  • Wolverine Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 12 quarters.
  • Wolverine Asset Management's Avadel Pharmaceuticals position peaked at $97.4K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.